中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

477 records (took 0.021 seconds)

    DNA SEQUENCING AND EPIGENOME ANALYSIS
    152.
    发明申请
    DNA SEQUENCING AND EPIGENOME ANALYSIS 审中-公开
    DNA序列和分析

    公开(公告)号：US20160168632A1

    公开(公告)日：2016-06-16

    申请号：US14909582

    申请日：2014-08-01

    Applicant: Jeremy Scott EDWARDS ,  STC.UNM

    Inventor： Jeremy Scott Edwards

    IPC: C12Q1/68

    CPC classification number: C12Q1/6874 ,  C12Q1/6825 ,  C12Q1/6841 ,  C12Q2523/303 ,  C12Q2543/10 ,  C12Q2523/307

    Abstract: This disclosure describes, in one aspect, methods for DNA sequencing and performing epigenomic analyses. Generally, the methods include immobilizing a plurality of copies of a DNA molecule on a surface, stretching at least a portion of the immobilized DNA molecules, and sequencing at least a portion of the immobilized, stretched DNA molecules.

    Abstract translation: 本公开在一个方面描述了用于DNA测序和进行表观基因组分析的方法。 通常，所述方法包括将多个拷贝的DNA分子固定在表面上，拉伸固定的DNA分子的至少一部分，以及测序至少一部分固定的，拉伸的DNA分子。

    Methods and related compositions for the treatment of cancer
    153.
    发明授权
    Methods and related compositions for the treatment of cancer 有权
    用于治疗癌症的方法和相关组合物

    公开(公告)号：US09326974B2

    公开(公告)日：2016-05-03

    申请号：US14449957

    申请日：2014-08-01

    Applicant: STC.UNM

    Inventor： Todd A. Thompson ,  Debra Mackenzie ,  Tudor I. Oprea ,  Larry A. Sklar ,  Bruce S. Edwards ,  Mark Haynes

    IPC: A01N43/66 ,  A61K31/437 ,  A61K31/165 ,  A61K31/445 ,  A61K31/135 ,  A61K45/06 ,  A61N5/10

    CPC classification number: A61K31/437 ,  A61K31/135 ,  A61K31/165 ,  A61K31/445 ,  A61K45/06 ,  A61N5/10

    Abstract: A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.

    Abstract translation: 治疗和/或预防癌症的方法包括在癌细胞中引起增加的细胞内颗粒度的给药剂，至少足以抑制这些细胞增殖的量，优选以足以导致癌细胞死亡的量。 该方法特别涉及难治性癌症，特别是激素难治性前列腺癌。 所鉴定的试剂导致癌细胞中的细胞内颗粒度增加，并且将粘附的癌细胞转化为非贴壁癌细胞，导致癌细胞死亡。 使用本发明，癌细胞在相对低的药物浓度下经历增加的细胞内粒度，同时也抑制细胞增殖。 增加的浓度导致粘附的癌细胞转化为非粘附的癌细胞，然后转移到细胞死亡。 虽然癌细胞降解和死亡的确切机制尚未完全了解，但治疗的癌细胞（包括难治性前列腺癌细胞）通过自噬机制给予细胞死亡的指示。 还公开了与目前公开的方法相关的药物组合物。

    POROUS NANOPARTICLE-SUPPORTED LIPID BILAYERS (PROTOCELLS) FOR TARGETED DELIVERY AND METHODS OF USING SAME
    154.
    发明申请
    POROUS NANOPARTICLE-SUPPORTED LIPID BILAYERS (PROTOCELLS) FOR TARGETED DELIVERY AND METHODS OF USING SAME 审中-公开
    用于定向输送的多孔纳米脂质载体（PROTOCELLS）及其使用方法

    公开(公告)号：US20160106671A1

    公开(公告)日：2016-04-21

    申请号：US14970998

    申请日：2015-12-16

    Applicant: STC.UNM ,  SANDIA CORPORATION

    Inventor： C. Jeffrey Brinker ,  Eric C. Carnes ,  Carlee Erin Ashley ,  Cheryl L. Willman

    IPC: A61K9/127 ,  C12N15/113 ,  A61K39/05 ,  A61K31/711 ,  A61K31/704 ,  A61K33/24

    CPC classification number: A61K9/1271 ,  A61K31/704 ,  A61K31/711 ,  A61K33/24 ,  A61K38/00 ,  A61K39/05 ,  A61K45/06 ,  A61K47/62 ,  A61K47/6901 ,  A61K48/0016 ,  C07K14/47 ,  C12N15/1135 ,  C12N15/88 ,  C12N2310/14 ,  C12N2320/32 ,  C12N2810/40

    Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

    Abstract translation: 本发明涉及用于特异性靶向肝细胞和其它癌细胞的原细胞，其包含具有支持的脂质双层的纳米多孔二氧化硅核心; 至少一种促进癌细胞死亡的药物（例如传统的小分子，大分子货物（例如siRNA或蛋白质毒素如蓖麻毒素A链或白喉毒素A链）和/或组蛋白包装的质粒DNA 设置在纳米多孔硅芯内（优选超螺旋以更有效地将DNA包装到原细胞中），其任选地用核定位序列修饰以帮助定位癌细胞核内的原细胞，以及表达参与治疗的肽的能力 （凋亡/细胞死亡）或作为报告物，靶向肽靶向待治疗的组织中的癌细胞，使得原细胞与靶细胞的结合是特异性和增强的，并且促进内体逃逸的融合肽 原细胞和包封的DNA。根据本发明的原细胞可用于治疗癌症，特别是包括肝细胞（肝）癌症 选择性结合肝细胞组织或在癌症诊断中起作用的新型结合肽（c-MET肽），包括癌症治疗和药物发现。

    Wafer level integration of focal plane arrays having a flexible conductive layer to provide an optical aperture for each pixel
    155.
    发明授权
    Wafer level integration of focal plane arrays having a flexible conductive layer to provide an optical aperture for each pixel 有权
    具有柔性导电层的焦平面阵列的晶片级集成，以为每个像素提供光学孔

    公开(公告)号：US09318517B1

    公开(公告)日：2016-04-19

    申请号：US14290619

    申请日：2014-05-29

    Applicant: STC.UNM

    Inventor： John A Montoya ,  Sanjay Krishna ,  Stephen Myers

    IPC: H01L27/146

    CPC classification number: H01L27/14687 ,  H01L27/14632 ,  H01L27/14634

    Abstract: Apparatus, systems, and methods related to focal plane arrays can be used in a variety of applications. In various embodiments, focal plane arrays can be fabricated on a wafer integration level based on arrangement of a flexible conductive layer for photosensitive pixels of the focal plane arrays. Arrangement of a flexible conductive layer allows for a number of architectures of focal plane arrays. Additional apparatus, systems, and methods are disclosed.

    Abstract translation: 与焦平面阵列相关的装置，系统和方法可用于各种应用中。 在各种实施例中，基于用于焦平面阵列的感光像素的柔性导电层的布置，可以在晶片集成度上制造焦平面阵列。 柔性导电层的布置允许多个焦平面阵列的架构。 公开了附加装置，系统和方法。

    High-Q optical resonators and method of making the same
    156.
    发明授权
    High-Q optical resonators and method of making the same 有权
    高Q光谐振器及其制作方法

    公开(公告)号：US09285535B2

    公开(公告)日：2016-03-15

    申请号：US13960659

    申请日：2013-08-06

    Applicant: STC.UNM

    Inventor： Ravinder K. Jain ,  Mani Hossein-Zadeh

    IPC: C03B37/15 ,  G02B6/02 ,  G02B6/26 ,  H01S3/06 ,  G02B6/12 ,  H01S3/16 ,  H01S3/17

    CPC classification number: G02B6/02052 ,  G02B6/262 ,  G02B2006/12038 ,  G02B2006/12109 ,  G02B2006/12159 ,  G02B2006/12169 ,  H01S3/0627 ,  H01S3/1608 ,  H01S3/173

    Abstract: An optical resonator made from an elongated fiber having a proximal and distal end. A sphere is created on the distal end by locating the distal end in cylindrically symmetrical heating zone along a centerline. For some embodiments, the distal end is rapidly cooled by allowing it to retract away from the heating zone along the centerline during the formation and solidification of the molten microsphere. The resulting optical resonator has an intrinsic quality factor greater than 106 over the 2.0 to 3.2 μm MIR wavelength range.

    Abstract translation: 由具有近端和远端的细长纤维制成的光学谐振器。 通过将远端沿着中心线定位在圆柱对称的加热区域中，在远端产生球体。 对于一些实施例，远端在熔融微球体的形成和凝固过程中允许其沿着中心线从加热区域缩回而快速冷却。 所得光学谐振器在2.0至3.2μmMIR波长范围内具有大于106的固有品质因数。

    ONLINE REVIEW ASSESSMENT USING MULTIPLE SOURCES
    157.
    发明申请
    ONLINE REVIEW ASSESSMENT USING MULTIPLE SOURCES 审中-公开
    在线评估使用多个来源

    公开(公告)号：US20160070709A1

    公开(公告)日：2016-03-10

    申请号：US14849227

    申请日：2015-09-09

    Applicant: STC.UNM

    Inventor： Shuang Luan ,  Abdullah Mueen ,  Michalis Faloutsos ,  Amanda J. Minnich

    IPC: G06F17/30

    CPC classification number: G06Q30/0282

    Abstract: Multiple sources of reviews for the same product or service (e.g. hotels, restaurants, clinics, hair saloon, etc.) are utilized to provide a trustworthiness score. Such a score can clearly identify hotels with evidence of review manipulation, omission and fakery and provide the user with a comprehensive understanding of the reviews of a product or establishment. Three types of information are used in computing the score: spatial, temporal and network or graph-based. The information is blended to produce a representative set of features that can reliably produce the trustworthiness score. The invention is self-adapting to new reviews and sites. The invention also includes a validation mechanism by crowd-sourcing and fake review generation to ensure reliability and trustworthiness of the scoring.

    Abstract translation: 使用同一产品或服务（例如酒店，餐馆，诊所，发廊等）的多个评论来源来提供可信度得分。 这样的分数可以清楚地识别具有审查操作，遗漏和虚假的证据的酒店，并向用户全面了解产品或机构的审查。 在计算分数时使用三种类型的信息：空间，时间和网络或基于图形。 信息被混合以产生可靠地产生可信度得分的代表性特征集合。 本发明适应新的评论和网站。 本发明还包括通过采购和假审查生成的验证机制，以确保得分的可靠性和可信度。

    TARGETING ABNORMAL DNA REPAIR IN THERAPY-RESISTANT BREAST AND PANCREATIC CANCERS
    158.
    发明申请
    TARGETING ABNORMAL DNA REPAIR IN THERAPY-RESISTANT BREAST AND PANCREATIC CANCERS 审中-公开
    针对耐药性乳腺癌和胰腺癌的异常DNA修复

    公开(公告)号：US20160051517A1

    公开(公告)日：2016-02-25

    申请号：US14793878

    申请日：2015-07-08

    Applicant: STC.UNM ,  UNIVERSITY OF MARYLAND, BALTIMORE

    Inventor： Alan Edward Tomkinson ,  Feyruz Rassool

    IPC: A61K31/4184 ,  C12Q1/68 ,  G06F19/20 ,  A61K31/165

    CPC classification number: A61K31/4184 ,  A61K31/00 ,  A61K31/165 ,  A61K45/06 ,  C12Q1/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57434 ,  G06F19/00 ,  G06F19/20 ,  G06F19/3456 ,  Y02A90/26 ,  A61K2300/00

    Abstract: In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject.In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.

    Abstract translation: 在一个实施方案中，本发明提供了治疗患有对抗雌激素疗法无反应或本质上抗性的乳腺癌肿瘤的受试者的方法，其包括施用治疗有效量的替代（ALT）非同源末端的抑制剂 加入（NHEJ）因素。 在另一个实施方案中，本发明提供了治疗患有对化学疗法和/或放射线无反应的胰腺癌的受试者的方法，包括向受试者共同施用治疗有效量的PARP1抑制剂和DNA连接酶IIIα抑制剂。 还提供了相关的诊断方法，核酸阵列，装置和试剂盒。

Patent Agency Ranking